Nykode Therapeutics AS (OSL:NYKD)
kr 3.256 -0.034 (-1.03%) Market Cap: 1.07 Bil Enterprise Value: -265.37 Mil PE Ratio: 0 PB Ratio: 0.61 GF Score: 46/100

Q2 2024 Nykode Therapeutics ASA Earnings Call Transcript

Aug 21, 2024 / 02:00PM GMT
Release Date Price: kr5.56 (-47.04%)
Operator

Greetings, and welcome to the Nykode Therapeutics Q2 2024 financial results presentation. (Operator Instructions) As a reminder, this conference is being recorded.

It's now my pleasure to introduce your host, CEO, Michael Engsig. Please go ahead, sir.

Michael Engsig
Nykode Therapeutics ASA - Chief Executive Officer

Thank you very much, Kevin and also from our side, a very warm welcome to all participants at this webcast to go through the second quarter of Nykodes.

Of course, with me today, I'm pleased to have Agnete Fredriksen, Chief Scientific Officer and Head of Business Development. Harald Gurvin, our Chief Finalcial Officer; and Klaus Edvardsen, Head of Research and Development. We assume your're all familiar with our forward-looking statements. So on that note, we'll just quickly skip forward.

So as first quarter has been another eventful quarter. And in addition to that, we have this morning also announced a strategic repositioning, which we'll take you further through.

So I'm going to give you a brief run-on of the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot